PURPOSE: Auger electrons emitted by radioisotopes such as 125I have a high linear energy transfer and short mean-free path in tissue (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. The authors developed and subsequently investigated a cancer cell-selective small molecule phospholipid ether analog to deliver 125I to triple-negative breast cancer (TNBC) cells in vivo. METHODS: A Current Good Manufacturing Practice (cGMP) method to radiolabel 125I-CLR1404 (CLR 125) with >95% radiochemical purity was established. To estimate CLR 125 in vivo dosimetry and identify dose-limiting organs, the biodistribution of the analog compound 124I-CLR1404 (CLR 124) was investigated using micro-positron emission tomography (PET)/computed tomography (CT) in conjunction with a Monte Carlo dosimetry platform to estimate CLR 125 dosimetry. In vivo antitumor efficacy was tested by injecting nude mice bearing either MDA-MB-231-luc orthotopic xenografts or lung metastases with 74 MBq (3.7 GBq/kg) of CLR 125 or an equivalent mass amount of nonradiolabeled CLR 125. Longitudinal tumor measurements using calipers and bioluminescence imaging were obtained for the xenografts and lung metastases, respectively. RESULTS: Dosimetry analysis estimated that CLR 125 would impart the largest absorbed dose to the tumor per injected activity (0.261 ± 0.023 Gy/MBq) while the bone marrow, which is generally the dose-limiting organ for CLR1404, appears to have the lowest (0.063 ± 0.005 Gy/MBq). At administered activities of up to 74 MBq (3.7 GBq/kg), mice did not experience signs of toxicity. In addition, a single dose of CLR 125 reduced the volume of orthotopic primary TNBC xenografts by ∼60% compared to control vehicle (p < 0.001) and significantly extended survival. In addition, CLR 125 was efficacious against preclinical metastatic TNBC models by inhibiting the progression of micrometastases (p < 0.01). CONCLUSIONS: Targeted radionuclide therapy with CLR 125 displayed significant antitumor efficacy in vivo, suggesting promise for treatment of TNBC micrometastases.
PURPOSE: Auger electrons emitted by radioisotopes such as 125I have a high linear energy transfer and short mean-free path in tissue (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. The authors developed and subsequently investigated a cancer cell-selective small molecule phospholipid ether analog to deliver 125I to triple-negative breast cancer (TNBC) cells in vivo. METHODS: A Current Good Manufacturing Practice (cGMP) method to radiolabel 125I-CLR1404 (CLR 125) with >95% radiochemical purity was established. To estimate CLR 125 in vivo dosimetry and identify dose-limiting organs, the biodistribution of the analog compound 124I-CLR1404 (CLR 124) was investigated using micro-positron emission tomography (PET)/computed tomography (CT) in conjunction with a Monte Carlo dosimetry platform to estimate CLR 125 dosimetry. In vivo antitumor efficacy was tested by injecting nude mice bearing either MDA-MB-231-luc orthotopic xenografts or lung metastases with 74 MBq (3.7 GBq/kg) of CLR 125 or an equivalent mass amount of nonradiolabeled CLR 125. Longitudinal tumor measurements using calipers and bioluminescence imaging were obtained for the xenografts and lung metastases, respectively. RESULTS: Dosimetry analysis estimated that CLR 125 would impart the largest absorbed dose to the tumor per injected activity (0.261 ± 0.023 Gy/MBq) while the bone marrow, which is generally the dose-limiting organ for CLR1404, appears to have the lowest (0.063 ± 0.005 Gy/MBq). At administered activities of up to 74 MBq (3.7 GBq/kg), mice did not experience signs of toxicity. In addition, a single dose of CLR 125 reduced the volume of orthotopic primary TNBC xenografts by ∼60% compared to control vehicle (p < 0.001) and significantly extended survival. In addition, CLR 125 was efficacious against preclinical metastatic TNBC models by inhibiting the progression of micrometastases (p < 0.01). CONCLUSIONS: Targeted radionuclide therapy with CLR 125 displayed significant antitumor efficacy in vivo, suggesting promise for treatment of TNBC micrometastases.
Entities:
Keywords:
Auger electrons; CLR1404; targeted radionuclide therapy; theranostics; triple-negative breast cancer
Authors: J Hickson; S Ackler; D Klaubert; J Bouska; P Ellis; K Foster; A Oleksijew; L Rodriguez; S Schlessinger; B Wang; D Frost Journal: Cell Death Differ Date: 2010-01-08 Impact factor: 15.828
Authors: Jamey P Weichert; Paul A Clark; Irawati K Kandela; Abram M Vaccaro; William Clarke; Marc A Longino; Anatoly N Pinchuk; Mohammed Farhoud; Kyle I Swanson; John M Floberg; Joseph Grudzinski; Benjamin Titz; Anne M Traynor; Hong-En Chen; Lance T Hall; Christopher J Pazoles; Perry J Pickhardt; John S Kuo Journal: Sci Transl Med Date: 2014-06-11 Impact factor: 17.956
Authors: Joseph J Grudzinski; John M Floberg; Sarah R Mudd; Justin J Jeffery; Eric T Peterson; Alice Nomura; Ronald R Burnette; Wolfgang A Tomé; Jamey P Weichert; Robert Jeraj Journal: Phys Med Biol Date: 2012-03-07 Impact factor: 3.609
Authors: E C Barendswaard; J L Humm; J A O'Donoghue; G Sgouros; R D Finn; A M Scott; S M Larson; S Welt Journal: J Nucl Med Date: 2001-08 Impact factor: 10.057
Authors: Il Minn; Ying Chen; Ana P Kiess; Robert Hobbs; George Sgouros; Ronnie C Mease; Mrudula Pullambhatla; Colette J Shen; Catherine A Foss; Martin G Pomper Journal: J Nucl Med Date: 2015-07-16 Impact factor: 10.057
Authors: Isabella Castellano; Elena Allia; Valeria Accortanzo; Anna Maria Vandone; Luigi Chiusa; Riccardo Arisio; Antonio Durando; Michela Donadio; Gianni Bussolati; Alan S Coates; Giuseppe Viale; Anna Sapino Journal: Breast Cancer Res Treat Date: 2010-02-03 Impact factor: 4.872
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: Ian R Marsh; Joseph Grudzinski; Dana C Baiu; Abigail Besemer; Reinier Hernandez; Justin J Jeffery; Jamey P Weichert; Mario Otto; Bryan P Bednarz Journal: J Nucl Med Date: 2019-03-29 Impact factor: 10.057
Authors: Justin C Jagodinsky; Won Jong Jin; Amber M Bates; Reinier Hernandez; Joseph J Grudzinski; Ian R Marsh; Ishan Chakravarty; Ian S Arthur; Luke M Zangl; Ryan J Brown; Erin J Nystuen; Sarah E Emma; Caroline Kerr; Peter M Carlson; Raghava N Sriramaneni; Jonathan W Engle; Eduardo Aluicio-Sarduy; Todd E Barnhart; Trang Le; KyungMann Kim; Bryan P Bednarz; Jamey P Weichert; Ravi B Patel; Zachary S Morris Journal: Theranostics Date: 2021-04-15 Impact factor: 11.600